GIC Private Ltd 13D and 13G filings for Revance Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-10-23 7:17 pm Sale | 2024-09-30 | 13G | Revance Therapeutics, Inc. RVNC | GIC Private Ltd | 0 0.000% | -5,825,881 (Position Closed) | Filing |
| 2024-02-09 10:05 am Purchase | 2023-12-31 | 13G | Revance Therapeutics, Inc. RVNC | GIC Private Ltd | 5,825,881 6.630% | 332,916 (+6.06%) | Filing |
| 2023-02-09 2:10 pm Purchase | 2022-12-31 | 13G | Revance Therapeutics, Inc. RVNC | GIC Private Ltd | 5,492,965 6.680% | 1,316,885 (+31.53%) | Filing |
| 2022-02-08 5:07 pm Purchase | 2021-12-31 | 13G | Revance Therapeutics, Inc. RVNC | GIC Private Ltd | 4,176,080 5.820% | 345,129 (+9.01%) | Filing |
| 2021-02-12 4:32 pm Purchase | 2020-12-31 | 13G | Revance Therapeutics, Inc. RVNC | GIC Private Ltd | 3,830,951 5.760% | 865,400 (+29.18%) | Filing |
| 2020-03-13 4:22 pm Purchase | 2020-03-04 | 13G | Revance Therapeutics, Inc. RVNC | GIC Private Ltd | 2,965,551 5.210% | 2,965,551 (New Position) | Filing |